KPIs & Operating Metrics(New)
Adult Nutritionals Revenue By RegionAdult Nutritionals Revenue By Region AnnualAssets By SegmentBreakdown Of AssetsCapital ExpenditureCore Laboratory Revenue By RegionCore Laboratory Revenue By Region AnnualCovid Test Diagnostic Revenue By RegionCovid Test Diagnostic Revenue By Region AnnualCovid Test Revenue By CategoryCovid Test Revenue By Category AnnualDiabetes Care Revenue By RegionDiabetes Care Revenue By Region AnnualDiagnostics Revenue By TestsDiagnostics Revenue By Tests AnnualDiagonostics Revenue By CategoryDiagonostics Revenue By Category AnnualElectrophysiology Revenue By RegionElectrophysiology Revenue By Region AnnualEmployee StstisticsEstablished Pharmaceutical Revenue By CategoryEstablished Pharmaceutical Revenue By Category AnnualGross MarginGross Margin%Heart Failure Revenue By RegionHeart Failure Revenue By Region AnnualIncome Before Income Tax By RegionInternational Revenue By Geographic AreaManufacturing Facilities Count By SegmentMedical Devices Revenue By CategoryMedical Devices Revenue By Category AnnualMolecular Revenue By RegionMolecular Revenue By Region AnnualNeuromodulation Revenue By RegionNeuromodulation Revenue By Region AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Nutritionals Revenue By CategoryNutritionals Revenue By Category AnnualOperating Earnings By SegmentOperating Earnings By Segment AnnualOperating Margin By Segment %Operating Margin By Segment Annual %Opex As A % Of Total Revenue %OPEX SegregationPediatric Nutritionals Revenue By RegionPediatric Nutritionals Revenue By Region AnnualPoint Of Care Revenue By RegionPoint Of Care Revenue By Region AnnualProperty, Plant And Equipment, Net BreakdownRapid Diagnostics Revenue By RegionRapid Diagnostics Revenue By Region AnnualRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Rhythm Management Revenue By RegionRhythm Management Revenue By Region AnnualStructural Heart Revenue By RegionStructural Heart Revenue By Region AnnualVascular Revenue By RegionVascular Revenue By Region Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Abbott Laboratories (ABT) Gross Margin (2009 - 2026)

Abbott Laboratories recorded quarterly Gross Margin of 56.2% in Q1 2026, down 1.49% quarter-over-quarter from 57.05% in Q4 2025, and down 67.0% year-over-year from 170.3% in Q1 2025.

Abbott Laboratories' Gross Margin history runs 18 years deep, the most recent figure standing at 56.2% for Q1 2026.

  • In Q1 2026, Gross Margin fell 67.0% year-over-year to 56.2%; the TTM figure through Mar 2026 stood at 56.26% (up 45.0% YoY), while the FY2025 annual figure was 56.42%, up 101.0% from the prior year.
  • Gross Margin came in at 56.2% for Q1 2026 at Abbott Laboratories, down from 57.05% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 58.07% in Q1 2022 to a low of 54.48% in Q4 2022.
  • A 5-year average of 55.8% and a median of 55.57% in 2023 frame the typical range for Gross Margin.
  • On a YoY basis, Gross Margin climbed as much as 457 bps in 2022 and fell as far as 399 bps in 2022.
  • Abbott Laboratories' Gross Margin stood at 54.48% in 2022, then climbed by 2 bps to 55.51% in 2023, then slipped by 1 bps to 54.97% in 2024, then climbed by 4 bps to 57.05% in 2025, then slipped by 1 bps to 56.2% in 2026.
  • According to Business Quant data, Gross Margin over the past three periods registered 56.2%, 57.05%, and 55.36% for Q1 2026, Q4 2025, and Q3 2025 respectively.